Prospective Comparison of SGLT-2 inhibitor, Luseogliflozin, versus GLP-1 Receptor Agonist,Dulaglutide, on Regression of Coronary Atherosclerosis with Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes, Acute coronary syndrome
- Registration Number
- JPRN-jRCTs031180408
- Lead Sponsor
- Aso Yoshimasa
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Provision of informed consent before any study specific procedures
1 Age from 20 to 80 years old
2 Gender free , Both
3 history of cardiovascular complications and post angioplasty
4 Type 2 diabetes who have inadequate glycemic control . less than 6.0%(HbA1c)
excluded to administration of SGLT2 inhibitor, GLP-1 receptor agonist
1; Type I diabetes, Diabetes related from pancreas dysfunction
2; Diabetic ketoacidosis, Diabetic coma, and sever infection
3; contraindication to SGLT-2 inhibitor and GLP-1 receptor agonist on Attachments
4; Heart disease, Liver disease (hepatic enzymes more than three times the upper limit of normal ranges) or Impaired kidney function
5; acute heart failure (NYHA IV)
6; familial hypercholesterolemia (Homozygous)
7; Pregnancy or suspicion of pregnancy
8; Administration of SGLT2 inhibitor,GLP-1 receptor agonist before starting trial.
9; User of PCSK9 inhibitor
10; Patients judged as nonconforming in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Regression lesion of atheromatous arteriosclerosis plaque by IVUS in coronary artery
- Secondary Outcome Measures
Name Time Method BNP,NT proBNP ,renal tubular function, Hematopoietic capability, inflammatory cytokine,<br>ROS, vascular function (RHI), HbA1c,